Janus kinase (JAK) Inhibitors – Insights Into the Marketed and Emerging Pipeline Drugs | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

 Breaking News
  • No posts were found

Janus kinase (JAK) Inhibitors – Insights Into the Marketed and Emerging Pipeline Drugs | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

March 01
23:54 2023
Janus kinase (JAK) Inhibitors - Insights Into the Marketed and Emerging Pipeline Drugs | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
DelveInsight Business Research LLP
As per DelveInsight’s assessment, about 40+ key pharma and biotech companies are working on 45+ pipeline drugs in the Janus kinase (JAK) inhibitors Competitive landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Janus kinase (JAK) Inhibitors Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Janus kinase (JAK) Inhibitors Market. 

The Janus kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Janus kinase (JAK) Inhibitors Pipeline Analysis

Janus kinase (JAK) Inhibitors Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging Janus kinase (JAK) Inhibitors in the market and the aggregate therapies developed by major pharma companies.

  • It accesses the different Janus kinase (JAK) Inhibitors therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Janus kinase (JAK) Inhibitors Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Janus kinase (JAK) Inhibitors by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Major Clinical, Commercial, and Regulatory Developments in the Janus kinase (JAK) inhibitors Market:

  • In July 2022, AbbVie announced that it had submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn’s disease.

  • In March 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) had approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for RINVOQ in gastroenterology and is supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinical studies. 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Janus kinase (JAK) Inhibitors Therapeutic Segment @ 


Key Companies in the Janus kinase (JAK) Inhibitors Therapeutics Market Include:

  • AbbVie

  • Aclaris Therapeutics

  • Arcutis Biotherapeutics

  • Celon Pharma

  • Dizal Pharmaceutical

  • Galapagos

  • Gilead Sciences

  • Incyte Corporation

  • Jiangsu Hengrui Medicine Co.

  • Novartis

  • Pfizer

  • Reistone Biopharma

  • Sierra Oncology

  • Theravance Biopharma

And Many Others

Janus kinase (JAK) Inhibitors Covered and Analyzed in the Report Include:

  • ATI-2138: Aclaris Therapeutics

  • CPL409116: Celon Pharma

  • Filgotinib: Galapagos

  • Golidocitinib: Dizal Pharmaceutical

  • Itacitinib: Incyte Corporation

  • Ivarmacitinib: Arcutis Biotherapeutics/Reistone Biopharma

  • Momelotinib: Sierra Oncology

  • Nezulcitinib: Theravance Biopharma

  • RINVOQ: AbbVie

  • Ritlecitinib: Pfizer

  • Ruxolitinib: Incyte Corporation/Novartis

  • TD 5202: Theravance Biopharma

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Janus kinase (JAK) Inhibitors Current Treatment Patterns

4. Janus kinase (JAK) Inhibitors – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Janus kinase (JAK) Inhibitors Late Stage Products (Phase-III)

7. Janus kinase (JAK) Inhibitors Mid-Stage Products (Phase-II)

8. Janus kinase (JAK) Inhibitors Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Janus kinase (JAK) Inhibitors Discontinued Products

13. Janus kinase (JAK) Inhibitors Product Profiles

14. Key Companies in the Janus kinase (JAK) Inhibitors Market

15. Key Products in the Janus kinase (JAK) Inhibitors Therapeutics Segment

16. Dormant and Discontinued Products

17. Janus kinase (JAK) Inhibitors Unmet Needs

18. Janus kinase (JAK) Inhibitors Future Perspectives

19. Janus kinase (JAK) Inhibitors Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 



Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles